The aim was to analyze the effectiveness of treatment concerning obesity-associated comorbidities in clinical practice. METHODS: A total of 11 681 overweight children with X6-month follow-up treated at 175 centers specialized in pediatric obesity care in Central Europe were included in this analysis (mean body mass index (BMI) 29.0 ± 5.6 kg m À 2 , standard deviation score body mass index (SDS-BMI) 2.48±0.54, 45% boys, age 11.4±2.8 years). The changes of weight status, blood pressure, fasting lipids and glucose, and oral glucose tolerance tests were documented by standardized prospective quality documentation software (APV). RESULTS: After follow-up of in median 1.2 (interquartile range 0.9-2.2) years, a mean reduction of À 0.15 SDS-BMI was achieved. The prevalence of prehypertension (37-433%) and hypertension (17-412%) decreased, while prevalences of triglycerides 4150 mg dl À 1 (22-421%), low-density-lipoprotein-cholesterol 4130 mg dl À 1 (15-414%), impaired fasting glucose (6-46%) and impaired glucose tolerance (9-48%) remained stable. Drug treatment according to cutoffs recommended in European obesity guidelines were not frequently indicated (hypertension: 10%; dyslipidemia: 1%, type 2 diabetes o1%). None of the children with dyslipidemia received lipid-lowering drugs and only 1.4% of the children with hypertension were treated with antihypertensive drugs. CONCLUSIONS: Achieving sufficient weight loss to improve obesity associated comorbidities was difficult in clinical practice. Drug treatment of hypertension, dyslipidemia and type 2 diabetes was rarely performed even if it was indicated only in a minority of the overweight children. Future analyses should identify reasons for this insufficient drug treatment of comorbidities and analyze whether the benchmarking processes of APV improve medical care of childhood obesity.
INTRODUCTION
Childhood obesity is increasing worldwide. 1 Obese subjects are frequently characterized by hypertension, impaired glucose metabolism, reduced high-density-lipoprotein (HDL)-cholesterol, increased total cholesterol, low-density-lipoprotein (LDL)-cholesterol and triglycerides summarized in the metabolic syndrome.
1,2 Such a metabolic profile increases the long-term risk for cardiovascular diseases and non-insulin-dependent diabetes. 3, 4 International current guidelines recommend the measurement of blood pressure in connection with lipids (triglycerides, cholesterol, LDL-and HDL-cholesterol) and a screening for impaired glucose metabolism in obese children and adolescents as diagnostic procedures. [5] [6] [7] If weight loss is not achievable, comorbidities should be treated by drugs following these guidelines. [5] [6] [7] However, data in clinical practice concerning implementation and efficiency of these guidelines are missing. Surveys in the USA claim the lack of medical centers for obese children and adolescents. 8, 9 Furthermore, a previous study in Central Europe reported that blood pressure, lipids and glucose were determined in o50% of obese children. 10, 11 In order to study the current situation, we analyzed a large data set consisting of 411 000 overweight and obese children and adolescents participating in a lifestyle intervention. This data set has been generated in clinical practice in Central Europe (Germany, Austria and Switzerland) outside of the ideal circumstance of a study to analyze (1) the prevalence of hypertension, dyslipidemia and abnormal glucose metabolism; (2) the improvement of blood pressure, dyslipidemia and hyperglycemia in a follow-up X6 months and (3) the initiation of drug treatment according to pediatric obesity guidelines.
PATIENTS AND METHODS
Based on the European and German guidelines for diagnostics and treatment of overweight children and adolescents, 6 a computer software based on the visual foxpro 9.0 compiler was developed for standardized prospective documentation (APV) in 1999 (www.a-p-v.de). 10 Participating in this quality control program is a precondition for accreditation of obesity treatment centers by the German Obesity Society (DAG) and for funding of the treatment by health insurances in Germany. Anthropometric parameters, metabolic control and treatment modalities are documented longitudinally by the software. The software allows standardized patient reports, local aggregation of data and patient selection according to multiple criteria. Anonymized data are transmitted for central analysis twice yearly. Inconsistent and missing data are reported back to the centers for correction. Each participating center complies with its local ethical and data management guidelines.
The weight status was recorded as body mass index (BMI). Overweight was defined as a BMI above the 90th and below the 97th percentile, obesity as a BMI equal or above the 97th and below the 99.5th percentile and extreme obesity as a BMI equal or above the 99.5th percentile, the latter corresponding to a BMI X40 kg m À 2 in adults. Population-specificbased reference data were used as recommended by the International Task Force of Obesity. 12, 13 The degree of overweight was quantified using Cole's box cox-transformation, which normalizes the BMI skewed distribution in childhood and expresses BMI as a standard deviation score (SDS-BMI). 14 A total of 175 treatment centers specialized in pediatric obesity care in Germany, Austria, and Switzerland participated in this study. Specialized centers are defined by accreditation of obesity treatment centers by the German Obesity Society (DAG) and by health insurances in Germany. Briefly, the accreditation process is based on quality criteria such as personal competence (multidisciplinary team with at least 1 year treatment experience in childhood obesity, team consisting of pediatricians, psychologists, exercise trainer and dietitians), intervention based on behavior therapy, exercise therapy and dietary advice for both children and parents, adequate rooms for cooking, exercise therapy and group counseling, as well as training manuals for children, parents and therapists according to the guidelines of the German Obesity Society. Therefore, specialized centers are defined on both competence and commitment to follow the predefined treatment strategy according to the guidelines of the German Obesity Society. 6 Overweight and obese patients were treated according to the same guideline. 6 All overweight and obese patients aged 2-20 years, with the first visit before March 2011 and a follow-up of at least 6 months, were included in the analysis. All subjects presented to participate in a lifestyle intervention.
Cardiovascular risk factors (blood pressure, fasting total cholesterol, LDLand HDL-cholesterol, fasting triglycerides, fasting glucose, and oral glucose tolerance test (oGTT)) were recorded in compliance with European and German guidelines for overweight children. 6 Cutoff points of
) for triglycerides, 5.6 mmol l À 1 (100 mg dl À 1 ), respectively, 7.0 mmol l À 1 (126 mg dl À 1 ) for fasting blood glucose and 7.8 mmol l À 1 (140 mg dl), respectively, 11.1 mmol l À 1 (200 mg dl À 1 ) for blood glucose after 2 h in the oGTT were used according to WHO recommendations 7 and the guidelines of the German pediatric working group on metabolic disorders. 15 Blood pressure was measured according to international guidelines. 16 Pre-hypertension was defined by repeated blood pressure values above the 90th percentile and hypertension by repeated blood pressure values above the 95th percentile according to German representative data. 17 Furthermore, the prevalence of (pre-) hypertension was studied according to the references from US (fourth task force report 16 
RESULTS
A total of 11 681 children and adolescents were included in the analyses (mean BMI 29.0 ± 5.6 kg m À 2 , SDS-BMI 2.48 ± 0.54, 45% boys, age 11.4 ± 2.8 years). Thirteen percent of these children were overweight, 45% obese and 42% extreme obese. The completeness of blood pressure, lipids and glucose determinations at initial presentation and at follow-up is demonstrated in Figure 1 . Children with complete diagnostic work-up of their cardiovascular risk factor profile were younger (11.4 versus 12.7 years; P ¼ 0.001) and less overweight (2.4 versus 2.5 SDS-BMI; Po0.001), but did not differ in sex (P ¼ 0.768).
The number of children recruited per year increased during the study period: 502 children were included in the The follow-up period was in median 1.2 years (interquartile range 0.9-2.2 years). At follow-up, a significant (Po0.001) but only moderate degree of weight loss were present (in mean À 0.16 SDS-BMI). Degree of weight loss (as SDS-BMI) were significant related to treatment duration (r ¼ 0.09, Po0.001).
The mean SDS-blood pressure levels decreased significantly between first presentation and follow-up (see Table 1 ). Degree of weight loss (as SDS-BMI) was related significantly to decreases of systolic blood pressure (r ¼ 0.11, Po0.001) and diastolic blood pressure (r ¼ 0.09, Po0.001). Treatment duration was not significantly related to changes of systolic blood pressure (P ¼ 0.423) or diastolic blood pressure (P ¼ 0.316). The prevalence of (pre-) hypertension according to different definitions was decreased significantly in follow-up. Separating the children to age demonstrated similar findings (see Table 2 ), while only obese and extreme obese children but not overweight children demonstrated a decrease of blood pressure values or percentage of (pre-) hypertension (see Table 3 ).
A total of 2668 children demonstrated a blood pressure above the 90th percentile both at baseline evaluation as well as at X6-month follow-up (see Table 4 ). Blood pressure values above cutoffs to initiate drug treatment had 987 children at initial presentation and 854 children demonstrated blood pressure values 495th percentile also at follow-up. Therefore, 10% of the 8364 children with blood pressure values at baseline and at follow-up should have received drug treatment according to guidelines. At baseline, eight (o1%) of these 987 children with documented blood pressure values 495th percentile received an antihypertensive drug treatment. At X6-month follow-up, additional 12 children (which means 1.4% of the 853 children with repeated documented blood pressure values 495th percentile) received an antihypertensive drug treatment. Antihypertensive drug treatment was initiated five times in the years 1999-2007 and 15 times in the years 2008-2011.
In the X6-month follow-up, triglycerides and cholesterol levels as well the prevalence of hypertriglyceridemia and Figure 1 . Completeness of blood pressure, fasting lipids and fasting glucose measurements as well as realization of oGTT in 11 681 overweight children both at baseline and at X6-month follow-up.
Medical care of overweight children T Reinehr et al hypercholesterolemia decreased significantly but only slightly (see Table 1 ). Separating the children to age demonstrated an improvement of lipids predominately in the children X10 years (see Table 2 ). In contrast to overweight children, obese and extreme obese children showed a significant improvement of their lipids (see Table 3 ). Degree of weight loss (as SDS-BMI) was related significantly to decreases of cholesterol (r ¼ 0.08, Po0.001), LDL-cholesterol (r ¼ 0.10, Po0.001) and triglycerides (r ¼ 0.10, Po0.001). Degree of weight loss (as SDS-BMI) was related significantly to an increase of HDL-cholesterol (r ¼ 0.07, Po0.001). Treatment duration was not significantly related to changes of triglycerides (P ¼ 0.822), LDL-cholesterol (P ¼ 0.938) and HDL-cholesterol (P ¼ 0.362). A total of 33 (0.5%) children of the 7286 children with repeated fasting lipids values demonstrated triglycerides 4400 mg dl À 1 both at baseline and at follow-up, which should be treated by drugs according to guidelines. None of these 33 children with documented repeated triglycerides 4400 mg dl À 1 received lipidlowering drugs (see Table 4 ). A total of 36 (0.5%) children of the 7286 children with repeated fasting lipids values demonstrated LDL-cholesterol concentrations 4190 mg dl À 1 both at baseline and at follow-up, which should be treated by drugs according to guidelines. None of these 36 children with documented repeated LDL-cholesterol levels 4190 mg dl À 1 received lipid-lowering drugs (see Table 4 ).
Fasting glucose levels, 2-h glucose levels in oGTT, as well as prevalences of impaired fasting glucose tolerance and impaired fasting glucose remained stable in the X6-month follow-up (see Table 1 ). Separating the children to degree of overweight showed similar findings (see Table 3 ). Separating the children to age demonstrated an improvement of 2-h glucose in oGTT only in children X10 years, while fasting glucose remained stable independent of age (see Table 2 ). Degree of weight loss (as SDS-BMI) was related significantly to decreases of fasting glucose (r ¼ 0.07, Po0.001) and 2-h glucose in oGTT (r ¼ 0.05, Po0.001). Treatment duration was significantly but only very weakly related to changes of fasting glucose (r ¼ 0.04; P ¼ 0.023), while treatment duration was not related to changes of 2-h glucose in oGTT (P ¼ 0.912).
None of the patients manifested with severe diabetes requiring insulin treatment. One child demonstrated HbA1c levels 47% both at baseline (HbA1c 7.6%) and in X6-month follow-up (HbA1c 8.4% 2.7 years after baseline). This child did not receive any drug treatment. At baseline, four children with impaired glucose tolerance were treated with metformin, and at X6-month follow-up 19 children with impaired glucose tolerance were treated with metformin.
DISCUSSION
This is the first longitudinal study in clinical practice of a very large group of patients in a broad multicenter cooperation in Europe addressing the quality of medical care for cardiovascular risk factors in overweight children and adolescents outside of the ideal circumstances of a study. The most striking findings are the low degree of overweight reduction and the lack of drug treatment of obesity-associated comorbidities even if weight loss was not achievable. However, cardiovascular risk factors were rarely repetitively above the thresholds to initiate drug treatment (hypertension: 10% of the children, severe dyslipidemia: B1% children, diabetes type 2: o1% children).
In contrast, our study demonstrates that (pre-) hypertension, moderate dyslipidemia and impaired glucose metabolism are already present frequently in obese predominantly Caucasian children and adolescents. In agreement with previous reports, 2,18-20 one third of the overweight children and adolescents suffer from (pre-) hypertension. Increased levels of triglycerides, cholesterol, and LDL-cholesterol have been described in 10-40% of obese children and adolescents, while decreased levels of HDL-cholesterol were found in up to 10%, 2, [18] [19] [20] according to our study. In concordance with other studies in Caucasian populations, 2,21,22 impaired glucose metabolism (6%) and silent diabetes mellitus (B1%) was rarely diagnosed compared with studies in the United States detecting impaired glucose tolerance in 25% and diabetes mellitus in 4% of the screened obese children and adolescents. 23 Differences could be explained at least in part by the different ethnical subgroups. 7 The failure to achieve clinical relevant weight loss in most children are in line to previous reports 10, 11, [24] [25] [26] [27] [28] and may be attributed to several points such as certain characteristics of overweight patients and their families (for example, lack of psychosocial support and parenting skills), changing motivation for lifestyle changes, inadvertent constraints to therapy adherence, or insufficient efficacy and/or quality of lifestyle interventions. 26 In contrast to these disappointing findings, we have previously reported that even in clinical practice besides from the ideal circumstance of a study a success rate of nearly 50% under an intention-to-treat approach is possible in the best treatment centers. 26 Moreover, we have to keep in mind that some previous studies reported an increase of BMI z-score in Medical care of overweight children T Reinehr et al untreated overweight and obese children and adolescents. [29] [30] [31] Therefore, a near stable SDS-BMI may represent a positive course in obese children and adolescents. Treatment of cardiovascular risk factors is mandatory even in childhood as these factors are associated to early vascular changes already in overweight children 32 and accordingly increase mortality and morbidity. 33, 34 As effective weight loss was not achieved in many of the overweight children and adolescents in our study (mean SDS-BMI reduction 0.16 while an improvement of cardiovascular risk factors have been reported by a reduction of X0.5 SDS-BMI 35, 36 ), it is not surprising that most of the cardiovascular risk factors did not improve considerably in the X6-month follow-up period. Accordingly, the number of children with hypertriglyceridemia, hypercholesterolemia, impaired fasting glucose, impaired glucose tolerance and diabetes changed only marginally. These findings suggest a relative ineffectiveness of medical care.
It was a surprising finding that only very few children were treated with antihypertensive or lipid-lowering drugs even at follow-up, when it was evident that no effective weight loss was achievable and the documented values for blood pressure and lipids were repeatedly above the cutoffs to initiate drug treatment according to European guidelines. 6, 15 It seems that pediatricians in Europe have great concerns in the use of these drugs in childhood obesity. Studies from other parts of the world are missing, but it seems not unlikely that the situation is similar. For example, the recommendations to use drugs treating comorbidities of childhood obesity in the guidelines of the Endocrine Society are vague. They do not advice specific cutoffs when to use drugs. 37 The reasons for the neglect of medical treatment of comorbidities in childhood obesity in Europe are unclear and have to be analyzed in further studies. One can speculate that fear of side effects, hope for spontaneous improvement, vague recommendations in guidelines and no personal experience with catastrophic vascular events may explain at least in part the rare use of drugs. Also, given the lack of continuity and follow-up with many obese patients, many practitioners may feel it is not appropriate to start pharmacological therapy unless the family is compliant enough to return to the clinic so that the physician can assess the patient for potential side effects of the medications. If no specific treatment follows the diagnosis of cardiovascular risk factors, screening as recommend in several guidelines [5] [6] [7] is questionable in childhood obesity. In our study, recommended diagnostic procedures were sometimes missed (especially measurements of fasting lipids and glucose) in a cohort of specialized medical centers, demonstrating a gap between guidelines and reality in medical care of overweight children and adolescents. However, the findings in this study (determination of blood pressure in 470%, fasting lipids in 460% and fasting glucose in 450%) at initial presentation and at follow-up are better than the results of a study in the United States reporting a measurement of lipids in B50% and glucose metabolism in 15% of obese children and adolescents presenting in specialized treatment centers for obesity. 10 Interestingly, the completeness of diagnostic procedures has been improved in our study compared with a similar analysis 7 years ago in the same institutions with the APV documentation system: in this study, we have reported a measurement of blood pressure in only 43%, lipids in 40% and fasting glucose in 21% of all overweight children presenting at obesity treatment institutions. 10 If this improvement is based on an increased screening in clinical practice, this finding points toward that a documentation system like APV can help to improve diagnostic procedures. This effect can be explained by the fact Table 2 . Blood pressure, lipids and glucose metabolism as well as prevalence of (pre-) hypertension, dyslipidemia, impaired fasting glucose, impaired glucose tolerance in children with follow-up of least 6 months after initial presentation separated to age o10 years X10 years 17 1.1 ± 1.6
1.0 ± 1.5* 1.1 ± 1.6 0.9 ± 1.4* SDS-diastolic blood pressure (German reference) 17 0.8 ± 1.6 0.6 ± 1.5* 1.0 ± 1.7 0.6 ± 1.6* Pre-hypertension (German reference) 17 
31%
29% 
Abbreviations: HDL, high-density-lipoprotein; LDL, low-density-lipoprotein; oGTT, oral glucose tolerance test; SDS, standard deviation score; Data as percentage or mean and standard deviation or median and interquartile range if not normally distributed, *Po0.001 baseline compared with follow-up.
Medical care of overweight children T Reinehr et al that centers not confirming to the recommendations get feedback on missing procedures. This may improve the quality of care as previously demonstrated with the DPV documentation software in patients with diabetes mellitus. 38 Hopefully, the quality control program APV may also improve the weight loss, probably the patient adherence, and the initiation of indicated drug treatment of cardiovascular risk factors. The threefold increase of antihypertensive drug use in the past three years compared with the previous years of recruitment points toward this positive effect. Due to the benchmarking process, all treatment centers can be compared identifying the best treatment institutions. This can help treatment centers to learn from each other.
The strengths of this study are the large study sample, the multi-center design and the longitudinal analysis in clinical practice, not under ideal circumstances of a study trial probably overestimating the effects. However, we have to notice some important limitations of this study. First, not all obesity treatment centers in the analyzed region participated in this study. Nevertheless, the most specialized treatment centers are likely to be enrolled in this observational study at least in Germany, as participating in the APV quality program is necessary for funding of the interventions by German health insurances and accreditation of obesity treatment centers. Second, children with type 2 diabetes are registered in another quality database (DPV) in Central Europe. 21 Therefore, we cannot calculate the prevalence rate of type 2 diabetes in Central Europe based on our registry. Further limitations are that the methods used for the measurement of blood pressure, lipids and blood glucose may differ and the indications for diagnostic procedures seem to vary between the institutions. Therefore, the prevalence of cardiovascular risk factors in our study has to be interpreted cautiously. In addition, the number of children included per year in this study increased with the study duration probably influencing the results. However, this increasing recruitment points toward acceptance of the quality program APV in clinical practice. Finally, measurements may have been performed and drug treatment may have been initiated but not documented. But without documentation the value of a diagnostic procedure is questionable.
In summary, structures for the medical care of obese children and adolescents have to be improved. In clinical practice, a sufficient weight loss to improve the cardiovascular risk factor profile was not achievable in many patients. Even if severe hypertension and dyslipidemia, which should be treated by drugs, did not occur frequently in our collective, we have to notice that these disorders were not treated adequately by drugs even if it was clear from the follow-up that effective weight loss cannot be achieved. The reasons for this neglect of drug treatment of comorbidities in childhood obesity have to be analyzed in further studies. The documentation of cardiovascular risk factors has been improved in Central Europe parallel to an implementation of a standardized evaluation program (APV). Future analyses will demonstrate whether the benchmarking processes of APV will also improve the process and structure of treatment procedures in childhood obesity and its comorbidities. Medical care of overweight children T Reinehr et al
